1-20 of 21
Ana Kostic
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Ciara Louise Freeman, Binod Dhakal, Gurbakhash Kaur, Richard T. Maziarz, Natalie Callander, Adam S. Sperling, Carolina Schinke, Andrzej J Jakubowiak, Noa Biran, Douglas W Sborov, Cindy Varga, Abhinav Deol, Abraham S. Kanate, Mehmet Hakan Koçoğlu, Melhem M. Solh, Kamalika Banerjee, Rebecca Chan, Myrna Nahas, Ana Kostic, Enrique Granados, Carolyn Jackson, Christopher R. Heery, Tim Welliver, Krina K. Patel, Matthew Frigault
Journal: Blood
Blood (2024) 144 (Supplement 1): 1031.
https://doi.org/10.1182/blood-2024-198499
Published: 2024
Journal Articles

Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis

Rahul Banerjee, Ken Hasegawa, Taha Itani, Monique Giordana, Enrique Granados, Margrit B Rosado, Rebecca J Chan, Ana Kostic, Steve Kanters, Michael J Zoratti, Xavier Leleu
Journal: Blood
Blood (2024) 144 (Supplement 1): 4721.
https://doi.org/10.1182/blood-2024-203741
Published: 2024
Journal Articles

Treatment Patterns and Outcomes in Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma: Findings from the Flatiron Database

Surbhi Sidana, Dhanalakshmi Thirumalai, Taha Itani, Elande Baro, Monique Giordana, Enrique Granados, Ken Hasegawa, Margrit B Rosado, Rebecca J Chan, Ana Kostic, Kamalika Banerjee, Krina K. Patel, Doris K. Hansen
Journal: Blood
Blood (2024) 144 (Supplement 1): 6962.
https://doi.org/10.1182/blood-2024-201119
Published: 2024
Journal Articles

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Michael R Bishop, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika Banerjee, Rebecca J Chan, Ana Kostic, Christopher R. Heery, Tim Welliver, David Avigan, Andrzej J Jakubowiak, Matthew Frigault
Journal: Blood
Blood (2024) 144 (Supplement 1): 4825.
https://doi.org/10.1182/blood-2024-201080
Published: 2024
Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Clinical Trials & Observations
Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi
Journal: Blood
Blood (2024) 143 (5): 404–416.
https://doi.org/10.1182/blood.2023020854
Published: 2024
Includes: Supplemental data
Journal Articles

Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety

Fabian Mueller, Julie Rytlewski, Chun Wu, Sarah Hu, Ashley Koegel, Nikolay Delev, Ana Kostic, Vaishali Shah, Thomas Wegman, Georg Schett
Journal: Blood
Blood (2023) 142 (Supplement 1): 6873.
https://doi.org/10.1182/blood-2023-174276
Published: 2023
Journal Articles

Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL

Michael L. Wang, Leo I. Gordon, Alexandre V Hirayama, Matthew A Lunning, Ling Shi, Shien Guo, Ana Kostic, Laurie Eliason, Jinender Kumar, Maria Lia Palomba
Journal: Blood
Blood (2023) 142 (Supplement 1): 667.
https://doi.org/10.1182/blood-2023-180014
Published: 2023
Journal Articles

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Pere Barba, Sally Lanar, Fei Fei Liu, Laurie Eliason, Kshawna Askew, Jennifer Devlen, Ulrika Furustrand, Ana Kostic
Journal: Blood
Blood (2023) 142 (Supplement 1): 7352.
https://doi.org/10.1182/blood-2023-178858
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Maria Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew A Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3505.
https://doi.org/10.1182/blood-2023-178109
Published: 2023
Journal Articles

Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

Nilanjan Ghosh, Alison R. Sehgal, Fei Fei Liu, Ana Kostic, Alessandro Crotta, Lily Peng, Marc De Benedetti, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 10430–10431.
https://doi.org/10.1182/blood-2022-159686
Published: 2022
Journal Articles

Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jerill Thorpe, Yue Jiang, Julie A Rytlewski, Ana Kostic, Yeonhee Kim, Leanne Peiser
Journal: Blood
Blood (2021) 138 (Supplement 1): 3834.
https://doi.org/10.1182/blood-2021-151790
Published: 2021
Journal Articles

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon E. Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Ana Kostic, Yeonhee Kim, Ken Ogasawara, Christine Dehner, Tanya Siddiqi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2840.
https://doi.org/10.1182/blood-2021-148948
Published: 2021
Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 241.
https://doi.org/10.1182/blood-2019-127508
Published: 2019
Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2868.
https://doi.org/10.1182/blood-2019-127566
Published: 2019
Journal Articles

Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

Max S. Topp, MD, Peter Borchmann, MD, Nina D. Wagner-Johnston, MD, Mariano Provencio, MD, Raul Cordoba, MDPhD, Kyriakos Papadopoulos, MD, Alejandro Martín, MD PhD, Carlos Grande, MD, Deepa Jagadeesh, MDMPH, Nehal Lakhani, MD PhD, Sven de Vos, MD PhD, Anthony R. Mato, MD, Uta Brunnberg, MD, Sebastian Scholl, MD, Christiane Pott, MD, PhD, Sarah C Rutherford, MD, Johannes Duell, MD, Lieve Adriaens, PharmD, Melanie Ufkin, BS, PhD, Ana Kostic, PhD, Anne Josee Paccaly, PharmD, PhD, Bo Gao, PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Cecilia Carpio, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1495.
https://doi.org/10.1182/blood.V130.Suppl_1.1495.1495
Published: 2017
Journal Articles

Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Ranjana H. Advani, MD, Jennifer R. Brown, MD PhD, Jon E. Arnason, MD, Jeffrey A. Barnes, MD PhD, John N. Allan, MD, Stephen M Ansell, MD PhD, Susan M. O'Brien, MD, Julio C. Chavez, MD, Lieve Adriaens, PharmD, Melanie Ufkin, BS, PhD, Ana Kostic, PhD, Anne Josee Paccaly, PharmD, PhD, Bo Gao, PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Max S. Topp, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1550.
https://doi.org/10.1182/blood.V130.Suppl_1.1550.1550
Published: 2017
Journal Articles

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jon Arnason, MD, Susan M. O'Brien, MD, John N. Allan, MD, Julio C. Chavez, MD, Jeffrey A. Barnes, MD PhD, Robin Joyce, MD, Stephen Ansell, MD PhD, Max S Topp, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ana Kostic, PhD, Anne Paccaly, PharmD, PhD, Bo Gao, PhD, Pamela A. Trail, PhD, Israel Lowy, MD PhD, Carrie Brownstein, MD
Journal: Blood
Blood (2016) 128 (22): 621.
https://doi.org/10.1182/blood.V128.22.621.621
Published: 2016
Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

Amir T Fathi, MD, Uma Borate, MD, Daniel J. DeAngelo, MD PhD, Maureen M. O'Brien, MD, Tanya Trippett, MD, Bijal D Shah, Gregory A. Hale, MD, James M. Foran, MD, Lewis B. Silverman, MD, Raoul Tibes, MD PhD, Stuart Cramer, D.O., Melinda Pauly, MD, Stella Kim, Ana Kostic, MD, Xiaohui Huang, Yang Pan, PhD, Robert Chen
Journal: Blood
Blood (2015) 126 (23): 1328.
https://doi.org/10.1182/blood.V126.23.1328.1328
Published: 2015
Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Craig H Moskowitz, Michelle A Fanale, Bijal D Shah, Ranjana H Advani, MD, Robert Chen, Stella Kim, Ana Kostic, Tina Liu, Joanna Peng, Andres Forero-Torres
Journal: Blood
Blood (2015) 126 (23): 182.
https://doi.org/10.1182/blood.V126.23.182.182
Published: 2015
Journal Articles

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Craig H. Moskowitz, MD, Andres Forero-Torres, MD, Bijal D. Shah, MD, Ranjana Advani, MD, Paul Hamlin, MD, Stella Kim, MD, Ana Kostic, MD, Larissa Sandalic, MS, Baiteng Zhao, PhD, Michelle A. Fanale, MD
Journal: Blood
Blood (2014) 124 (21): 1741.
https://doi.org/10.1182/blood.V124.21.1741.1741
Published: 2014